Akari’s nomacopanan an Orphan Drug in U.S. for HSCT-TMA

The FDA has granted orphan drug designation to Akari Therapeutics’ (NASDAQ:AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA).

A pivotal trial is expected to start in Q4 2019.

Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.

Shares were up 15% premarket.

https://seekingalpha.com/news/3495957-akaris-nomacopanan-orphan-drug-u-s-hsct-tma-shares-15-percent-premarket